Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.59 |
| ▸ | SIRT3 | Q9NTG7 | 6/20 | 0.59 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932972 | 1.00 | SIRT2 (0.61) | SIRT2SIRT1SIRT3TLR2HDAC1 | |
| SCHEMBL9933643 | 0.95 | SIRT2 (0.65) | SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL19139851 | 0.95 | SIRT2 (0.65) | SIRT2SIRT1SIRT3TLR2 | |
| SCHEMBL13311693 | 0.94 | HDAC1 (0.54) | SIRT2SIRT1SIRT3TLR2HDAC1 | |
| SCHEMBL9933646 | 0.93 | SIRT2 (0.60) | SIRT2SIRT1SIRT3TLR2HDAC1 | |
| SCHEMBL14877938 | 0.90 | TLR2 (0.66) | SIRT2SIRT1SIRT3TLR2KMT2A | |
| SCHEMBL17747040 | 0.90 | TLR2 (0.66) | SIRT2SIRT1SIRT3TLR2KMT2A | |
| SCHEMBL17747033 | 0.90 | TLR2 (0.66) | SIRT2SIRT1SIRT3TLR2KMT2A | |
| SCHEMBL17747061 | 0.90 | TLR2 (0.66) | SIRT2SIRT1SIRT3TLR2KMT2A | |
| SCHEMBL21326214 | 0.90 | TLR2 (0.66) | SIRT2SIRT1SIRT3TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2652134-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | GALK1, GALE, GALNT6 | SIRT2 1236/4885SIRT1 761/4885SIRT3 901/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | SIRT2 1236/4885SIRT1 761/4885SIRT3 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.